Skinspell Inc. – Trademark Portfolio

Entity Type: 03

Skinspell Inc. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include DEFANYA, DR.HIUMI, and SOMANOVA. The owner is based in Las Vegas, NV.

304 S. Jones Blvd #3867

Las Vegas, NV 89107

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

SOMANOVA
SOMANOVA
Registered 2025
DR.HIUMI
DR.HIUMI
Registered 2025
DEFANYA
DEFANYA
Registered 2024

Trademark Classifications

Skinspell Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Skinspell Inc. have?

Skinspell Inc. has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Skinspell Inc. file in?

Skinspell Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Skinspell Inc.'s most well-known trademarks?

Skinspell Inc.'s registered trademark portfolio includes well-known marks such as DEFANYA, DR.HIUMI, and SOMANOVA. These are among 3 currently registered trademarks in the portfolio.

What is Skinspell Inc.'s trademark registration success rate?

Skinspell Inc. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.